Wall Street analyst estimates for PAVmed Inc. (PAVM): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.63 | ||
| 2026-08-14 | $-0.87 | $-0.47 | -85.1% |
| 2026-05-15 | $-4.42 | $-0.69 | -540.6% |
| 2026-03-26 | $-2.05 | $-4.50 | +54.4% |
| 2025-11-13 | $-8.70 | $-5.10 | -70.6% |
| 2025-08-14 | $-22.20 | $-3.90 | -469.2% |
| 2025-05-14 | $-2.10 | $-8.71 | +75.9% |
| 2025-03-24 | $-1.80 | $-3.30 | +45.5% |
Valuation Ratios
| Price / Book | 0.70 |
| EV / EBITDA | -2.65 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | $500000 | $377000 | $2.5M | $3.0M | $71000 |
| Cost of Revenue | $3793 | $7110 | $9790 | $14226 | 0 | $585000 | $3.6M | $6.4M | $6.0M | $323000 |
| Gross Profit | -$3793 | -$7110 | -$9790 | -$14226 | 0 | -$85000 | -$3.2M | -$4.0M | -$3.0M | -$252000 |
| Research & Development | $1.7M | $2.6M | $4.3M | $6.6M | $11.0M | $19.8M | $25.3M | $14.3M | $5.9M | $4.49B |
| Selling, General & Admin | $3.9M | $5.4M | $6.3M | $7.7M | $12.4M | $34.3M | $60.7M | $48.5M | $36.2M | $17.17B |
| Operating Expenses | $5.7M | $8.0M | $10.6M | $14.3M | $23.4M | $54.3M | $87.8M | $64.8M | $41.4M | $21.6M |
| Operating Income | -$5.7M | -$8.0M | -$10.6M | -$14.3M | -$23.4M | -$54.4M | -$91.1M | -$68.8M | -$44.5M | -$21.8M |
| EBITDA | -$5.6M | -$11.2M | -$12.1M | -$16.7M | -$23.3M | -$55.9M | -$99.5M | -$75.7M | $29.7M | -$2.3M |
| Interest Expense | 0 | $724684 | $2.4M | $32667 | $53000 | 0 | $1.3M | $589000 | $45000 | $21000 |
| Pre-tax Income | -$5.7M | -$9.5M | -$18.2M | -$17.3M | -$35.9M | -$56.1M | -$103.2M | -$79.3M | $28.4M | -$2.5M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$5.7M | -$9.5M | -$18.0M | -$15.9M | -$34.3M | -$50.3M | -$89.0M | -$64.2M | $39.8M | $401000 |
| EPS | $-198.00 | $-346.50 | $-378.78 | $-249.27 | $-327.91 | $-293.92 | $-450.95 | $-274.92 | $99.15 | $-5.63 |
| EPS (Diluted) | $-198.00 | $-346.50 | $-378.78 | $-249.27 | $-327.91 | $-293.92 | $-450.95 | $-274.92 | $14.88 | $-5.63 |
| Shares Outstanding (Diluted) | $28827 | $29991 | $49503 | $67105 | $105405 | $172257 | $197947 | $241052 | $2.2M | $670466 |
Price
| Price | $3.92 |
| Market Cap | $25M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADVB · APVO · BMRA · BNR · DHAI · HSCS · IINN
Explore sector: Healthcare · Medical - Devices
More sections of PAVM: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks